These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19690211)

  • 1. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis.
    Treloar C; Rhodes T
    Qual Health Res; 2009 Sep; 19(9):1321-34. PubMed ID: 19690211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis.
    Rhodes T; Treloar C
    Addiction; 2008 Oct; 103(10):1593-603. PubMed ID: 18821870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research.
    Jones L; Atkinson A; Bates G; McCoy E; Porcellato L; Beynon C; McVeigh J; Bellis MA
    Int J Drug Policy; 2014 Mar; 25(2):204-11. PubMed ID: 24332457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinforced biographies among women living with hepatitis C.
    Olsen A; Banwell C; Dance P
    Qual Health Res; 2013 Apr; 23(4):531-40. PubMed ID: 23258115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
    Hopwood M; Treloar C
    Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The depiction of stigmatization in research about hepatitis C.
    Paterson BL; Backmund M; Hirsch G; Yim C
    Int J Drug Policy; 2007 Oct; 18(5):364-73. PubMed ID: 17854724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    Madden A; Hopwood M; Neale J; Treloar C
    PLoS One; 2018; 13(11):e0207226. PubMed ID: 30500863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experiences of UK patients with hepatitis C virus infection accessing phlebotomy: A qualitative analysis.
    Clements A; Grose J; Skirton H
    Nurs Health Sci; 2015 Jun; 17(2):214-22. PubMed ID: 25496414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.
    Munoz-Plaza CE; Strauss S; Astone-Twerell J; Jarlais DD; Gwadz M; Hagan H; Osborne A; Rosenblum A
    Int J Drug Policy; 2008 Feb; 19(1):71-8. PubMed ID: 18312822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group.
    Woolhouse S; Cooper E; Pickard A
    Int J Drug Policy; 2013 Nov; 24(6):550-7. PubMed ID: 23860471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irish injecting drug users and hepatitis C: the importance of the social context of injecting.
    Smyth BP; Barry J; Keenan E
    Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injecting drug users' understanding of hepatitis C.
    O'Brien S; Day C; Black E; Dolan K
    Addict Behav; 2008 Dec; 33(12):1602-5. PubMed ID: 18762384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
    Nguyen OK; Dore GJ; Kaldor JM; Hellard ME;
    Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.
    Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y
    Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peer-delivered hepatitis C testing and counselling: a means of improving the health of injecting drug users.
    Aitken CK; Kerger M; Crofts N
    Drug Alcohol Rev; 2002 Mar; 21(1):33-7. PubMed ID: 12189002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C in a new therapeutic era: Recontextualising the lived experience.
    Whiteley D; Whittaker A; Elliott L; Cunningham-Burley S
    J Clin Nurs; 2018 Jul; 27(13-14):2729-2739. PubMed ID: 28960567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow.
    McDonald SA; Hutchinson SJ; Cameron SO; Innes HA; McLeod A; Goldberg DJ
    Int J Drug Policy; 2012 Sep; 23(5):353-7. PubMed ID: 22421553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C treatment for injection drug users: a review of the available evidence.
    Hellard M; Sacks-Davis R; Gold J
    Clin Infect Dis; 2009 Aug; 49(4):561-73. PubMed ID: 19589081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everybody's got it, but...: situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton, Canada.
    Wozniak L; Prakash M; Taylor M; Wild TC
    Int J Drug Policy; 2007 Oct; 18(5):388-96. PubMed ID: 17854727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.